CISD2在脓毒症相关心肌损伤中的作用及其对28天预后的预测价值
该回顾性研究纳入85例成人脓毒症患者,按LVEF分为心肌损伤组(32例)与非心肌损伤组(53例),检测入ICU 24小时外周血单核细胞CISD2 mRNA。心肌损伤组CISD2 mRNA显著低于非心肌损伤组(0.41±0.09 vs 0.92±0.13 copy/μL,P<0.05),CISD2与心肌损伤显著相关(r=0.729,P<0.05)。CISD2低表达组28天生存时间显著短于高表达组(Log-rank χ²=5.601,P<0.05);多因素Logistic回归显示CISD2(OR=3.400,95%CI 1.026-11.264,P=0.045)和LVEF(OR=2.905,95%CI 1.029-8.199,P=0.044)为28天死亡的独立预测因素。ROC曲线显示CISD2预测28天死亡的AUC为0.733(95%CI 0.626-0.823),预测心肌损伤的AUC为0.790(95%CI 0.688-0.871)。细胞实验显示LPS组CISD2 mRNA、蛋白及细胞活性显著下降,过表达CISD2可逆转。
要点
- 脓毒症合并心肌损伤患者入ICU 24小时PBMC中CISD2 mRNA显著低于无心肌损伤者(0.41±0.09 vs 0.92±0.13 copy/μL,P<0.05)。
- CISD2低表达(<0.5 copy/μL)组28天生存时间显著短于高表达组(Log-rank χ²=5.601,P<0.05)。
- 多因素Logistic回归显示CISD2(OR=3.400,95%CI 1.026-11.264,P=0.045)和LVEF(OR=2.905,95%CI 1.029-8.199,P=0.044)为脓毒症28天死亡的独立预测因素。
- CISD2预测脓毒症28天死亡的敏感度80.00%、特异度66.67%、AUC 0.733(95%CI 0.626-0.823)。
- CISD2预测脓毒症心肌损伤的敏感度83.87%、特异度74.07%、AUC 0.790(95%CI 0.688-0.871)。
适用人群与场景
- 2023年1月至2024年1月入住齐齐哈尔医学院附属第三医院重症医学科的成人脓毒症患者85例。
- 按LVEF分为脓毒症心肌损伤组(LVEF<0.50或较基线下降≥10%)32例和脓毒症非心肌损伤组53例。
诊断标准与关键阈值
- 脓毒症相关心肌损伤判定标准:LVEF<0.50或LVEF较基线下降≥10%。
- CISD2 mRNA低表达组:CISD2 mRNA<0.5 copy/μL;高表达组:CISD2 mRNA≥0.5 copy/μL。
研究设计与关键结果
- 回顾性研究,纳入85例成人脓毒症患者,其中心肌损伤32例、非心肌损伤53例;CISD2低表达40例、高表达45例;28天存活60例、死亡25例。
- 心肌损伤组CISD2 mRNA显著低于非心肌损伤组(0.41±0.09 vs 0.92±0.13 copy/μL,P<0.05),CISD2与心肌损伤显著相关(r=0.729,P<0.05)。
- CISD2低表达组LVEF<0.50比例(67.50% vs 11.11%)、SOFA评分(15.63±2.15 vs 11.12±1.52)、APACHEⅡ评分(29.49±3.51 vs 22.41±2.61)均显著高于高表达组(均P<0.05),其他指标无显著差异。
- Kaplan-Meier生存曲线显示CISD2低表达组28天生存时间显著短于高表达组(Log-rank χ²=5.601,P<0.05)。
- 多因素Logistic回归显示CISD2(OR=3.400,95%CI 1.026-11.264,P=0.045)和LVEF(OR=2.905,95%CI 1.029-8.199,P=0.044)为28天死亡的独立预测因素。
- ROC曲线:CISD2预测28天死亡敏感度80.00%、特异度66.67%、AUC 0.733(95%CI 0.626-0.823);预测心肌损伤敏感度83.87%、特异度74.07%、AUC 0.790(95%CI 0.688-0.871)。
- 细胞实验:与对照组比较,LPS组CISD2 mRNA、蛋白表达及细胞活性显著降低;转染p-CISD2过表达质粒后CISD2 mRNA、蛋白表达及心肌细胞活性显著升高。
证据类型、等级与局限
- 证据类型:回顾性临床研究结合体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CISD2在脓毒症相关心肌损伤中发挥保护作用,对28天预后和心肌损伤有较好的预测价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the role of CDGSH iron-sulfur domain 2 (CISD2) in patients with sepsis-related myocardial injury (SMI) and its predictive value for 28-day prognosis and myocardial damage through clinical studies and cell experiments.
METHODS: A retrospective study was conducted. Adult patients diagnosed with sepsis admitted to the critical care medicine of Third Affiliated Hospital of Qiqihar Medical University from January 2023 to January 2024 were enrolled. The clinical data, laboratory indicators, expression level of CISD2 mRNA in peripheral blood mononuclear cells (PBMC) 24 hours after admission, and 28 days prognosis were collected. Patients were divided into SMI group [left ventricular ejection fraction (LVEF) < 0.50 or LVEF decreased by ≥ 10% from baseline] and sepsis non-myocardial injury group based on LVEF. The expression levels of CISD2 mRNA were compared between the two groups, and the correlation between CISD2 and myocardial injury was analyzed. Patients were divided into the low-expression group (CISD2 mRNA < 0.5 copy/μL) and the high-expression group (CISD2 mRNA ≥ 0.5 copy/μL) based on the expression of CISD2 mRNA, and into the survival group and the death group based on the prognosis at 28 days. The clinical characteristics were analyzed between the groups. Multivariate Logistic regression was used to analyze the independent predictors of 28-day mortality in patients with sepsis. The predictive value of CISD2 for myocardial damage and 28-day prognosis in patients with sepsis were evaluated by using the receiver operator characteristic curve (ROC curve). In addition, in vitro experiments using human AC16 cardiomyocytes was conducted. The cells were divided into control group, lipopolysaccharide (LPS) group, the LPS+transfection group with overexpression of CISD2 plasmid (LPS+p-CISD2 group), and the LPS + transfection group with negative control plasmid (LPS+p-NC group). The mRNA expression of CISD2 in cells were detected by real-time quantitative polymerase chain reaction (RT-qPCR), the protein expression of CISD2 in cells were detected by Western blotting, and the cell viability was determined by cell counting kit-8 (CCK-8).
RESULTS: A total of 85 sepsis patients were included, with 32 developing myocardial injury and 53 without myocardial injury. There were 40 cases of low expression of CISD2 and 45 cases of high expression of CISD2. At 28 days, 60 cases survived and 25 cases died. The mRNA expression of CISD2 in the SMI group was significantly lower than that in the sepsis non-myocardial injury group (copy/μL: 0.41±0.09 vs. 0.92±0.13, P < 0.05). CISD2 was significantly correlated with myocardial injury in patients with sepsis (r = 0.729, P < 0.05). The proportion of LVEF < 0.50 (67.50% vs. 11.11%), sequential organ failure score (SOFA: 15.63±2.15 vs. 11.12±1.52), and acute physiology and chronic health evaluation II (APACHEII: 29.49±3.51 vs. 22.41±2.61) in the CISD2 low-expression group were significantly higher than those in the CISD2 high-expression group (all P < 0.05), while there were no significantly differences in other indicators. The Kaplan-Meier survival curve showed that the 28-day survival time of sepsis patients with in the CISD2 low-expression group was significantly shorter than that in the CISD2 high-expression group (Log-rank test: χ 2 = 5.601, P < 0.05). The proportion of CISD2 low-expression and the proportion of LVEF < 0.50 in the survival group were both higher than those in the death group (80.00% vs. 33.33%, 64.00% vs. 26.67%, both P < 0.05), while there were no significantly differences in other indicators. Multivariate Logistic regression analysis showed that CIDS2 and LVEF were independent predictive factors for 28-day mortality in patients with sepsis [CIDS2: odds ratio (OR) = 3.400, 95% confidence interval (95%CI) was 1.026-11.264, P = 0.045; LVEF: OR = 2.905, 95%CI was 1.029-8.199, P = 0.044]. ROC curve analysis showed that when CISD2 was expressed at a low level, patients with sepsis were at high risk of death within 28 days and myocardial injury. The sensitivity of CISD2 in predicting the 28-day mortality of patients with sepsis was 80.00%, and the specificity was 66.67%, and the area under the curve (AUC) was 0.733 (95%CI was 0.626-0.823). The sensitivity of CISD2 in predicting myocardial injury in patients with sepsis was 83.87%, the specificity was 74.07%, and the AUC was 0.790 (95%CI was 0.688-0.871). In addition, compared with the control group, the mRNA and protein expressions of CISD2 as well as the cell activity in the LPS group were significantly decreased. The mRNA and protein expressions of CISD2 and the activity of cardiomyocytes transfected with p-CISD2 were significantly increased.
CONCLUSIONS: CISD2 plays a protective role in sepsis-associated myocardial injury and has good predictive value for 28-day prognosis and myocardial injury.
参考来源
- Hei B, Li X, Meng X, et al. [The role of CISD2 in sepsis-associated myocardial injury and its predictive value for 28-day prognosis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41146544. doi:10.3760/cma.j.cn121430-20250305-00216
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。